Teva Pharmaceuticals USA and Celltrion Healthcare have launched the fourth trastuzumab biosimilar, Herzuma, at a 10% discount to the cost of reference product Herceptin.
Three months after its FDA approval, a fourth trastuzumab biosimilar has been launched. Teva Pharmaceuticals USA and Celltrion Healthcare announced the market availability of Herzuma (trastuzumab-pkrb), an injectable biosimilar with the same indications as the Herceptin reference product.
The biosimilar arrival on market follows launches of other biosimilars for trastuzumab by Pfizer (Trazimera), Mylan/Biocon (Ogivri), Amgen/Allergan (Kanjinti). An additional trastuzumab biosimilar approved but not yet launched is Samsung Bioepis’ Ontruzant.
Herzuma is indicated for the treatment of breast cancer in the adjuvant setting, metastatic breast cancer, and metastatic gastric cancer.
The wholesale acquisition cost (WAC) for Herzuma 150 mg is $1402.50 and HERZUMA 420 mg is $3927, which is a 10% discount to the WAC of Herceptin, Teva and Celltrion said in a release. They said actual costs for Herzuma are expected to be lower because WAC does not account for rebates and further discounts that may apply.
“We are proud to make Herzuma available to patients in the United States living with HER2-positive breast and gastric cancers, and their providers,” said Brendan O’Grady, executive vice president, North America Commercial, Teva.
Teva and Celltrion also are partners on a biosimilar for rituximab, whose reference product is Rituxan. Teva and Celltrion’s version, Truxima, was approved November 28, 2018, and was launched in November 2019. The product also was being offered at a 10% discount to the list price of reference product. Truxima was made available at $845.55 for a 100-mg vial and $4227.75 for a 500-mg vial.
Although the reference rituximab also carries indications for inflammatory diseases including rheumatoid arthritis, Celltrion sought and received approval only for adults with CD20-positive, B-cell non-Hodgkin lymphoma (NHL) either as monotherapy or in combination with chemotherapy.
Related Stories
Pfizer Launches Trastuzumab Biosimilar
Pipeline Report: Oncology Biosimilars to Advance in 2020
Pfizer Touts Lower WAC of 3 Oncology Biosimilars as It Launches Rituximab Product
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.